Plasma microRNA vary in association with the progression of Alzheimer's disease.

ABSTRACT:

Introduction

Early intervention in Alzheimer's disease (AD) requires the development of an easily administered test that is able to identify those at risk. Focusing on microRNA robustly detected in plasma and standardizing the analysis strategy, we sought to identify disease-stage specific biomarkers.

Methods

Using TaqMan microfluidics arrays and a statistical consensus approach, we assessed plasma levels of 185 neurodegeneration-related microRNA, in cohorts of cognitively normal amyloid β-positive (CN-Aβ+), mild cognitive impairment (MCI), and Alzheimer's disease (AD) participants, relative to their respective controls.

Results

Distinct disease stage microRNA biomarkers were identified, shown to predict membership of the groups (area under the curve [AUC] >0.8) and w

SUBMITTER: Guevremont D 

PROVIDER: S-EPMC8817674 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature